FOR IMMEDIATE RELEASE
INNOVATIVE DRUG GIVES HOPE FOR ADVANCED PROSTATE CANCER PATIENTS
Breakthrough Development from Clovis Oncology Offers First PARP Inhibitor Confirmed in a Prostate Cancer Setting
Washington, D.C., May 17, 2020 – ZERO – The End of Prostate Cancer is celebrating the historic approval of Rubraca (Rucaparib), a first in its class PARP inhibitor for metastatic, castration-resistant prostate cancer patients. The approval of Rubraca by the U.S. Food and Drug Administration, and the development of this novel drug by Clovis Oncology, marks a significant step forward in treatment options for advanced prostate cancer patients.
Rubraca showed positive results in studies for patients with deleterious BRCA mutations. As a PARP inhibitor, Rubraca works to block cancer cells from repairing their damaged DNA. Rubraca is the first drug of its kind for prostate cancer, and is authorized for patients with highly advanced disease. For the first time, patients that have been treated with no or limited success via androgen receptor-directed therapy and chemotherapy have another option, and another reason to hope.
“This is an exciting and much-needed development for advanced prostate cancer patients that attacks the tumor’s genetics rather than its tissue,” said ZERO CEO and President Jamie Bearse. “Precision medicine is paving a bright future for additional new treatment options for patients who have had no other alternative pathways.”
“For too long, advanced prostate cancer patients have had too few treatment options,” said Patrice Brown, ZERO’s Vice President of Patient Programs and Advocacy. “This gives a patient and families who have often felt hopeless the possibility of more time with their loved ones.”
PARP inhibitors have become popular targets for cancer therapies in recent years, as many cancers are dependent on PARP. (PARP is a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase.) In previous studies, as well as studies involved in the development and trial of Rubraca, PARP inhibitors have proven effective in those with BRCA mutations, a mutation that is estimated to be present in about 10 percent of prostate cancer patients.
News of Rubraca’s approval was published late Friday afternoon. The press release, which includes safety and access information, is available here. For more on ZERO’s efforts to fuel and fund advanced prostate cancer research, visit zerocancer.org/advocacy.
About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We’re building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 86 cents of every dollar to research and programs. For more information, visit www.zerocancer.org.